Insider Monkey has processed numerous 13F filings of hedge funds and famous investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds and investors’ positions as of the end of the third quarter. You can find write-ups about an individual hedge fund’s trades on numerous financial news websites. However, in this article we will take a look at their collective moves and analyze what the smart money thinks of Cytosorbents Corp (NASDAQ:CTSO) based on that data.
Cytosorbents Corp (NASDAQ:CTSO) has seen an increase in hedge fund interest recently. CTSO was in 4 hedge funds’ portfolios at the end of the third quarter of 2015. There were 2 hedge funds in our database with CTSO positions at the end of the previous quarter. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as CytRx Corporation (NASDAQ:CYTR), Skullcandy Inc (NASDAQ:SKUL), and GulfMark Offshore, Inc. (NYSE:GLF) to gather more data points.
To most traders, hedge funds are assumed to be underperforming, outdated investment vehicles of the past. While there are over 8000 funds in operation today, Our experts look at the top tier of this group, approximately 700 funds. These investment experts watch over the majority of the hedge fund industry’s total asset base, and by following their top picks, Insider Monkey has found many investment strategies that have historically defeated the broader indices. Insider Monkey’s small-cap hedge fund strategy exceeded the S&P 500 index by 12 percentage points a year for a decade in their back tests.
With all of this in mind, let’s view the latest action regarding Cytosorbents Corp (NASDAQ:CTSO).
How have hedgies been trading Cytosorbents Corp (NASDAQ:CTSO)?
Heading into Q4, a total of 4 of the hedge funds tracked by Insider Monkey were long this stock, a change of 100% from one quarter earlier. With hedge funds’ positions undergoing their usual ebb and flow, there exists an “upper tier” of noteworthy hedge fund managers who were boosting their stakes significantly (or already accumulated large positions).
According to Insider Monkey’s hedge fund database, Skylands Capital, managed by Charles Paquelet, holds the number one position in Cytosorbents Corp (NASDAQ:CTSO). Skylands Capital has an $0.3 million position in the stock, comprising less than 0.1%% of its 13F portfolio. Sitting at the No. 2 spot is Israel Englander’s Millennium Management, with an $0.1 million position; the fund has less than 0.1%% of its 13F portfolio invested in the stock. Some other professional money managers with similar optimism comprise Matthew Hulsizer’s PEAK6 Capital Management, Ken Griffin’s Citadel Investment Group and Ken Griffin’s Citadel Investment Group.